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Background. To analyze the efﬁcacy of antifungal prophylaxis (AFP) with posaconazole and itraconazole in a
real-life setting of patients with acute myeloid leukemia (AML) during the ﬁrst induction of remission.
Methods. From January 2010 to June 2011, all patients with newly diagnosed AML were consecutively regis-
tered and prospectively monitored at 30 Italian hematological centers. Our analysis focused on adult patients who
received intensive chemotherapy and a mold-active AFP for at least 5 days. To determine the efﬁcacy of prophy-
laxis, invasive fungal disease (IFD) incidence, IFD-attributable mortality, and overall survival were evaluated.
Results. In total, 515 patients were included in the present analysis. Posaconazole was the most frequently
prescribed drug (260 patients [50%]) followed by ﬂuconazole (148 [29%]) and itraconazole (93 [18%]). When
comparing the groups taking posaconazole and itraconazole, there were no signiﬁcant differences in the baseline
clinical characteristics, whereas there were signiﬁcant differences in the percentage of breakthrough IFDs (18.9%
with posaconazole and 38.7% with itraconazole, P < .001). The same trend was observed when only proven/
probable mold infections were considered (posaconazole, 2.7% vs itraconazole, 10.7%, P = .02). There were no
signiﬁcant differences in the IFD-associated mortality rate, while posaconazole prophylaxis had a signiﬁcant
impact on overall survival at day 90 (P = .002).
Conclusions. During the last years, the use of posaconazole prophylaxis in high-risk patients has signiﬁcantly
increased. Although our study was not randomized, it demonstrates in a real-life setting that posaconazole pro-
phylaxis confers an advantage in terms of both breakthrough IFDs and overall survival compared to itraconazole
prophylaxis.
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Invasive fungal diseases (IFDs) are a leading cause of morbidi-
ty and mortality in severely neutropenic patients, especially in
patients with acute myeloid leukemia (AML) and allogeneic
hematopoietic stem cell transplant (allo-HSCT) recipients [1–
6]. In particular, ﬁrst induction chemotherapy may be consid-
ered the highest risk phase of treatment for development of
IFDs in patients with AML [7, 8].
To reduce the incidence of IFDs, various strategies have
been investigated and various results have been obtained. Pre-
vious meta-analytic studies support the use of antifungal pro-
phylaxis in allo-HSCT patients and suggest possible beneﬁts
in other patients, particularly those that have a high risk of
developing IFDs [9, 10].
In the last few years, posaconazole has been demonstrated
to signiﬁcantly impact the current use of antifungal prophy-
laxis. Two randomized clinical trials demonstrated that posa-
conazole prophylaxis was superior to ﬂuconazole or
itraconazole in reducing the incidence of IFDs in high-risk pa-
tients, namely, AML patients and allo-HSCT recipients with
severe graft-versus-host disease [11, 12]. Accordingly, interna-
tional guidelines highly recommend the use of posaconazole
prophylaxis in AML patients [13–15]. To conﬁrm these
results, some studies in real-life settings evaluating the poten-
tial beneﬁts of posaconazole have been reported [16–21].
The aim of the present study was to describe the use of an-
tifungal prophylaxis in current clinical practice and to investi-
gate the impact in terms of IFD incidence and clinical
outcome. In particular, we focused on posaconazole and itra-
conazole because these agents have antimold activity, and in-
vasive aspergillosis is the most frequent IFD in AML patients.
PATIENTS AND METHODS
The present prospective study was conducted in 30 hematolo-
gy wards of tertiary care centers or university hospitals located
throughout Italy from January 2010 to June 2011. All adult
patients with newly diagnosed AML undergoing ﬁrst remis-
sion-induction chemotherapy who received antifungal pro-
phylaxis were included in the registry and followed up.
Prophylaxis, which consisted of 400 mg of ﬂuconazole daily, a
2.5 mg/kg oral itraconazole solution twice daily, or 200 mg of
posaconazole thrice daily, was started 1–3 days prior to che-
motherapy and continued until neutrophil recovery reached
>0.5 × 109 neutrophils/L or when therapy was interrupted
because of a suspected or conﬁrmed IFD.
The data were entered prospectively into case report forms.
The ethics committee of each participating site approved the
use of the Epidemiological Survey on Invasive Fungal Infec-
tions in Hematological Malignancies (SEIFEM) registry.
This was a noninterventional study. Accordingly, the enroll-
ment of a patient had no impact on the standard clinical
practice of the hematology units that were involved. The last
patient was recorded on 30 June 2011 and follow-up was com-
pleted on 30 September 2011. A minimum follow-up of 90
days after completion of chemotherapy was requested.
For each patient, baseline data were recorded at the time of
admission including age, sex, weight, occupation, AML
subtype, and comorbidities. The following additional informa-
tion was also collected: risk factors (eg, central venous cathe-
ter, level and duration of neutropenia), performance status
(according to World Health Organization [WHO] grading),
AML treatment, and antifungal prophylaxis (administered
drug and duration).
The diagnostic workup was similar among all participating
centers and included the following tests: nasal, pharyngeal,
and rectal swabs at the time of admission; blood cultures and
chest radiography at onset of fever; galactomannan assays
twice weekly; and a chest computed tomography (CT) scan on
the fourth to seventh day of fever. Additional examinations
(eg, abdominal ultrasound scan, sinus or brain CT, skin
biopsy, bronchoalveolar lavage, or fundus examination) were
performed as required.
The IFD incidence was assessed within the ﬁrst 30 days
after chemotherapy had ended. Invasive fungal diseases were
classiﬁed according to the 2008 EORTC/MSG (European Or-
ganization for Research and Treatment of Cancer/Mycoses
Study Group) criteria [22].
The registry also included the following data regarding anti-
fungal therapy: employed drugs, dosage, and approach (eg,
empirical, preemptive, or target treatment) [23].
Mortality was considered attributable to the IFD (IFD-
attributable mortality) when patients died within 12 weeks from
the onset of a fever with microbiological, histological, or clinical
evidence of an active IFD and if other potential causes of death
could be excluded by the responsible physician [24]. All causes
of death within 12 weeks were recorded (overall mortality).
STATISTICAL ANALYSIS
Continuous variables were compared using Student t test
(normally distributed variables) or the Mann-Whitney U test
(nonnormally distributed variables). Categorical variables were
evaluated using the χ2 test or 2-tailed Fisher exact test. Values
are expressed as the mean ± standard deviation (SD) or
median (range; continuous variables) or as a percentage of the
group from which they were derived (categorical variables).
The effect of type of drug used for prophylaxis (posaconazole
or itraconazole) on survival of the patients was ﬁrst analyzed
with the Kaplan-Meier method and, in addition, with a Cox
proportional hazard model that was not adjusted for any vari-
able because no statistically signiﬁcant differences among
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clinical and demographic variables analyzed were observed
between the 2 groups (see Table 1).
Two-tailed tests were used to determine statistical signiﬁ-
cance; a P value of <.05 was considered signiﬁcant. All statisti-
cal analyses were performed with the Intercooled Stata
software program, version 11 for Windows (StataCorp,
College Station, Texas).
RESULTS
Over an 18-month period, 703 adult patients with newly diag-
nosed AML were enrolled in the study. In total, 127 patients
received only supportive care or palliative treatments and were
excluded from the present analysis. The remaining 576 AML
patients received conventional intensive chemotherapy. Pa-
tients who did not receive prophylaxis (33 cases), those who
received topical polyenes (16 cases), or those who received <5
days of systemic prophylaxis due to early interruption (7 pos-
aconazole, 3 ﬂuconazole, or 2 itraconazole) were considered
not eligible and were excluded from the present analysis (61
patients; Figure 1).
Among the 515 evaluable patients who were treated with
systemic prophylaxis, 260 received posaconazole prophylaxis
(50.4%), 148 ﬂuconazole (28.7%), and 93 itraconazole (18%);
14 patients received other antifungal agents (5 voriconazole, 1
caspofungin, and 8 liposomal amphotericin B). An overall
progressive increase in the use of posaconazole prophylaxis
was observed during the 18 months of the study, while a fairly
constant use of itraconazole and a marked reduction in the
ﬂuconazole prophylaxis was observed (Figure 2).
The overall IFD incidence (possible, probable, and proven)
observed in this cohort of patients was 22.3% (115 cases over
515 patients). Sixty percent of observed IFDs (62 cases) were
considered possible cases.
The aim of present study was to compare the 353 patients
who received the antimold prophylaxis posaconazole (n = 260)
to those who received itraconazole (n = 93).
Among the participating centers, no differences emerged in
the distribution of patients treated with either posaconazole or
itraconazole.
The primary characteristics of the 2 groups of patients are
shown in Table 1. No statistically signiﬁcant differences
emerged in terms of performance, sex, percentage of deep
neutropenic patients (neutrophils <0.5 × 109/L), duration of
neutropenia >7 days, prophylaxis duration, or the use of
central venous catheter. The posaconazole arm included
younger subjects and more patients who were treated with an-
thracycline-based chemotherapy protocols. The 2 populations
also had a comparable distribution of AML morphological and
biological characteristics (eg, promyelocytic morphology and
cytogenetic patterns).
Overall, the IFD incidence in the itraconazole arm was
38.7% (36/93 patients), which is signiﬁcantly higher than that
observed in the posaconazole arm (18.9% [49/260 patients],
P < .001; Table 2). Excluding possible cases in both groups, the
same trend was observed in terms of proven/probable mold
infections, which were 10.7% in the itraconazole group and
2.7% in the posaconazole group (P = .02).
In both groups, all proven/probable mold infections were
caused by Aspergillus strains, except for 1 case of Fusarium
species infection in the itraconazole group. Among the 6
proven yeast infections, 4 were caused by Candida strains (2
in each arm, respectively), 1 by Trichosporon (posaconazole
arm), and 1 by Geotrichum (itraconazole arm).
Despite antifungal prophylaxis, 110 of 353 patients (31.2%)
required a subsequent antifungal treatment; a signiﬁcantly
reduced use of frontline antifungal therapy was observed in
the posaconazole arm (69 patients [26.6%] in the posacona-
zole group vs 41 patients [45.1%] in the itraconazole group;
P = .001). Although there were no differences in the use of em-
pirical therapy, both preemptive and target approaches were
more frequently used in the itraconazole arm (14% in the itra-
conazole arm vs 4.6% in the posaconazole arm, P = .003; and
7% in the itraconazole arm vs 1.5% in the posaconazole arm,
P = .004, respectively).
Forty-nine of the 74 patients who started with a frontline
empirical approach (21 in the itraconazole arm and 53 in
the posaconazole arm) had a subsequent IFD diagnosis (16 in
Table 1. Clinical Characteristics of the Patients Treated in the 2
Study Arms
Itraconazole
(n = 93)
Posaconazole
(n = 260)
P
Value
Age, median (IQR) 60 (49–67) 56 (44–65) .08
Male 48 (52.2%) 117 (45.0%) .23
Duration of prophylaxis 21 (15–26) 21 (16–28) .70
Deep neutropenia
(PMN< 500/µL >7 d)
87 (93.5%) 240 (92.3%) .69
Duration of
neutropenia, d,
median (IQR)
22 (16–27.5) 23 (18–29) .25
CVC 75 (80.6%) 200 (76.9%) .45
Performance statusa
0–1 72 (77.4%) 204 (78.5%) .83
2–4 21 (22.6%) 56 (21.5%)
Anthracycline-based
chemotherapy
81 (87.1%) 242 (93.1%) .08
Primary AML 68 (73.1%) 198 (76.2%) .56
Data are presented as No. (%) unless otherwise specified.
Abbreviations: AML, acute myeloid leukemia; CVC, central venous catheter;
IQR, interquartile range; PMN, polymorphonuclear cells.
a According to World Health Organization grading.
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the itraconazole arm and 33 in the posaconazole arm). In 25
patients (5 in the itraconazole arm and 20 in the posaconazole
arm), diagnostic tests did not reveal any fungal disease, and
these patients were registered as FUO (fever of unidentiﬁed
origin; 7.3%).
There was a trend toward a reduced duration of antifungal
treatment (empirical, preemptive, and target) in the posacona-
zole arm (P = .05). A signiﬁcant increase in the use of AmB
lipid compounds (eg, L-AmB or lipid complex amphotericin B)
was observed after prophylaxis failure in the posaconazole
arm.
Overall, mortality was signiﬁcantly reduced in the posaco-
nazole arm (3.5% vs 9.7%, P = .02; Table 2). Kaplan-Meier
survival estimates at 90 days conﬁrmed the lower risks of mor-
tality associated with posaconazole prophylaxis (P = .002;
Figure 3). The Cox proportional hazards model demonstrates
that the mortality risk for the posaconazole group is 0.37
times the risk estimated for the itraconazole group (P = .003).
The overall and IFD attributable mortality rates were both
higher in the itraconazole arm (Table 2).
Nine patients (7 in posaconazole arm, 2.5% and 2 in itraco-
nazole arm, 2.1%) were not considered eligible for the study
because they received <5 days of prophylaxis due to side
effects. No severe adverse events were observed (WHO
grade > 3) that were attributable to posaconazole or itracona-
zole toxicity. No cases of increased cardiotoxicity for concom-
itant anthracycline-based chemotherapy were observed.
DISCUSSION
Two recent randomized trials demonstrated that posaconazole
prophylaxis has a higher efﬁcacy and an excellent safety
proﬁle in high-risk patients such as those with AML and allo-
HSCT recipients with graft-versus-host disease [11, 12]. Partic-
ularly in AML patients, posaconazole prophylaxis signiﬁcantly
impacted both the IFD incidence and the patients’ overall sur-
vival. Thus, it may be a valid alternative to old prophylactic
regimens. Additionally, international guidelines recommend
this approach because of the high level of evidence [13–15].
Figure 1. Flow chart of the study patients. Abbreviations: AML, acute myeloid leukemia; L-AmB, liposomal amphotericin B.
Figure 2. Trends in the use of different antifungal drugs used as pro-
phylaxis during the study period. Abbreviations: ﬂuco, ﬂuconazole; itra,
itraconazole; posa, posaconazole.
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In the last few years, some retrospective studies conducted
in real-life settings have been published to conﬁrm the results
obtained in the 2 prospective clinical trials [16–20]. In these
studies, the reported incidence of proven/probable IFDs
ranges from 0% to 5%, which conﬁrms the efﬁcacy of posaco-
nazole prophylaxis. However, these studies consisted of small
case series, and the patients were almost always compared to
historical controls or to patients receiving drugs without anti-
mold activity (ie, ﬂuconazole or oral polyenes).
One of the criticisms raised by the study performed by
Cornely et al was the lack of a direct comparison between
posaconazole and itraconazole [25]. In our study, we focused
our attention on 2 antifungal agents with known efﬁciencies
against molds in a homogeneous cohort of patients who were
newly diagnosed with AML and who received standard
chemotherapy.
Our data conﬁrm the previous results of both randomized
trials and real-life studies that posaconazole prophylaxis
reduces the overall incidence of IFDs. Furthermore, posacona-
zole signiﬁcantly reduced the number of febrile episodes re-
quiring intravenous antifungal treatment. This may also result
in an economical advantage. It is unknown whether the pa-
tients who developed breakthrough IFDs were those who did
not achieve adequate posaconazole plasma levels because ther-
apeutic drug monitoring in clinical practice is unavailable in
the majority of the participating centers.
Recent literature has debated whether the positive results
observed with posaconazole reﬂect a true reduction in the
number of IFD cases or rather the ability of posaconazole to
suppress galactomannan expression [26, 27]. The latter would
translate to an increased proportion of possible cases (with ra-
diological signs only) [28]. In our experience, the number of
possible cases was reduced, and this observation supports the
idea that posaconazole efﬁciently prevents IFDs.
However, the preemptive approach (based either on a galac-
tomannan test or on CT scan positivity) was less frequently
used in the posaconazole arm. Furthermore, it is worth noting
that posaconazole prophylaxis did not reduce the use of the
empirical approach. Twenty patients in the posaconazole arm
received an empirically administered antifungal therapy but
were classiﬁed as FUO.
The different prophylactic approaches did not impact the
spectrum of infection nor the response to treatment. Notably,
the overall IFD-attributable mortality rate was comparable
Table 2. Invasive Fungal Disease Incidence, Treatment, and
Outcome in the 2 Study Groups
Itraconazole
(n = 93)
Posaconazole
(n = 260) P Value
All IFDs 36 (38.7%) 49 (18.9%) <.001
Possible mold IFDs 23 (24.7%) 39 (15.0%) .03
Probable and proven
mold IFDs
10 (10.7%) 7 (2.7%) .02
Proven yeast IFDs 3 (3.2%) 3 (1.1%) .18
FUO who received
antifungal therapy
5 (5.4%) 20 (7.6%) .45
Frontline antifungal
approach of IFD
41 (45.1%) 69 (26.6%) .001
Empirical 21 (22.6%) 53 (20.3%) .49
Preemptive 13 (14.0%) 12 (4.6%) .003
Target 7 (7.0%) 4 (1.5%) .004
Median duration of
antifungal treatment, d
(IQR)
15 (10–22) 12 (8–15) .05
Empirical 12 (8.5–19) 11 (7–14) .27
Preemptive 15 (9.5–24) 14 (10–26) .62
Target 18 (5–20) 12.5 (10–18) .46
Antifungal drugs
employed
Lipid AmB (L-AmB,
ABLC)
17/41 (41.5%) 42/69 (60.9%) .05c
Caspofungin 12/41 (29.0%) 18/69 (26.1%) .72c
Voriconazole 9/41 (22.0%) 8/69 (11.6%) .15c
Other 3a/41 (7.3%) 1b/69 (1.4%) .14d
Overall mortality 9/93 (9.7%) 9/260 (3.5%) .02
Attributable mortality 4/93 (4.3%) 2/260 (0.8%) .04
For molds 4/93 (4.3%) 0/260 (0%) .005
For yeasts 0/93 (0%) 2/260 (0.8%) .54
Abbreviations: ABLC, lipid complex amphotericin B; FUO, fever of unidentified
origin; IFD, invasive fungal disease; IQR, interquartile range; L-AmB, liposomal
amphotericin B.
a Anidulafungin, posaconazole (from prophylactic to therapeutic doses 400
mg twice a day), itraconazole.
b Posaconazole (from prophylactic to therapeutic doses 400 mg twice a day).
c χ2 test.
d Fisher exact test.
Figure 3. Survival functions among patients treated with posaconazole
or itraconazole prophylaxis.
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between the 2 groups, while the number of deaths attributable
to molds was signiﬁcantly lower after posaconazole therapy.
This is in contrast to a previous observation that reported a
higher mortality rate due to breakthrough IFDs after posaco-
nazole prophylaxis [29]. It is worth noting that few rare fungal
agents were isolated and no cases of Mucorales were observed
in both prophylactic arms.
The most frequently used antifungal agents after azole pro-
phylaxis failure were lipid AmB compounds; a signiﬁcantly
higher percentage was used in the posaconazole arm. This
could be due to the higher percentage of the use of an empiri-
cal approach that was observed in our series. It is also possible
that voriconazole is not considered the best frontline approach
for invasive aspergillosis after the failure of a highly efﬁcacious
azole prophylaxis by some physicians (ie, with posaconazole).
This hypothesis should be conﬁrmed by an additional study.
Similarly to Cornely and colleagues [11], we found that pos-
aconazole prophylaxis was able to lower overall mortality, and
the mortality risk was 0.37 times the risk estimated for the
itraconazole group in a homogeneous cohort of AML patients.
It has recently been proven that IFDs may continue to affect a
patient’s outcome despite survival of the initial infection
because of its inﬂuence on subsequent chemotherapy regi-
mens [30, 31].
This survey analyzed the use of different prophylactic regi-
mens utilized in a real-life pattern. It is remarkable that posaco-
nazole, which is considered the drug of choice for AML, was
utilized in only 50% of our patients. However, there was an in-
creasing trend in use from 20% to 65% during the study period
(from January 2010 to June 2011). On the other hand, approxi-
mately 7% of patients did not receive systemic prophylaxis (no
prophylaxis or topic polyenes). This could be justiﬁed by the
fact that the group with no prophylaxis included many patients
with acute promyelocytic leukemia, which is a form treated with
chemotherapy that does not usually induce deep and prolonged
neutropenia.
Conversely, the exact reason for the use of the different
azoles for prophylaxis in the same center is unclear. No signif-
icant differences in the clinical characteristics emerged
between cases treated with posaconazole and those with itraco-
nazole. The only trend observed was that patients treated with
itraconazole were older. Therefore, it can be speculated that
physicians prefer to use newer triazoles in younger patients
undergoing more aggressive chemotherapies to reduce infec-
tious risks and possible negative effects on their treatment
schedule. It is not possible to exclude the possibility that this
patchy use of azoles could also be due to economic issues.
Despite the limitations of the study design (observational,
not interventional and unequal sample sizes in the posacona-
zole and itraconazole groups), our prospectively collected data
support the use of posaconazole prophylaxis in AML patients
during induction chemotherapy because the drug appeared to
provide advantages in terms of both IFD prevention and sur-
vival. The optimal management of breakthrough infections
remains to be determined as well as the usefulness and reli-
ability of diagnostic tools in this context [25].
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